Annexin Pharmaceuticals AB (publ) (STO: ANNX)

Market Cap	295.27M
Revenue (ttm)	n/a
Net Income (ttm)	-52.36M
Shares Out	532.98M
EPS (ttm)	-0.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	648,751
Open	0.522
Previous Close	0.550
Day's Range	0.520 - 0.564
52-Week Range	0.184 - 0.932
Beta	1.15
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 18, 2024

About ANNX

Annexin Pharmaceuticals AB (publ), a biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein. The company offers Annexin A5 to protect and repair blood vessels and counteract inflammation. Annexin Pharmaceuticals AB (publ) was founded in 2014 and is based in Stockholm, Sweden.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 4
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ANNX

Financial Performance

In 2023, Safeture AB's revenue was 56.35 million, an increase of 26.38% compared to the previous year's 44.59 million. Losses were -6.45 million, -62.17% less than in 2022.